Heilongjiang ZBD Pharmaceutical (603567) Fundamentals 2026 — Revenue Analysis | SniperIQ
Heilongjiang ZBD Pharmaceutical (603567) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥5.6B, trading at ¥5.91 on the SHH. This SniperIQ fundamentals page covers Heilongjiang ZBD Pharmaceutical's valuation, profitability (net margin -317.8%), revenue (¥798M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Heilongjiang ZBD Pharmaceutical's market cap?
Heilongjiang ZBD Pharmaceutical (603567) has a market capitalization of approximately ¥5.6B, trading at ¥5.91 on the SHH. Market cap moves with the live share price.
What is Heilongjiang ZBD Pharmaceutical's P/E ratio?
Heilongjiang ZBD Pharmaceutical's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Heilongjiang ZBD Pharmaceutical?
Heilongjiang ZBD Pharmaceutical runs a net profit margin of -317.8%, a gross margin of -80.1%, and an operating margin of -204.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Heilongjiang ZBD Pharmaceutical generate?
Heilongjiang ZBD Pharmaceutical reported revenue of ¥798M for fiscal year 2025, with net income of -¥1.4B and earnings per share (EPS) of -1.45. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Heilongjiang ZBD Pharmaceutical pay a dividend?
Heilongjiang ZBD Pharmaceutical offers a trailing dividend yield of about 2.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Heilongjiang ZBD Pharmaceutical financially healthy?
Heilongjiang ZBD Pharmaceutical carries a debt-to-equity ratio of 0.33x and a current ratio of 1.38x, with a market beta of 0.28. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Heilongjiang ZBD Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Heilongjiang ZBD Pharmaceutical (603567) the key facts are: market cap ¥5.6B, revenue ¥798M, 52-week range 4.21-13.48. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Heilongjiang ZBD Pharmaceutical's full fundamentals live
Get Heilongjiang ZBD Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.